Apollo Hospitals Enterprise FY26 Annual Earnings Summary

Quick-commerce players have entered the prescription business with aggressive discounts, potentially pressuring margins and customer acquisition costs.

International patient volumes from Bangladesh remain below pre-disruption levels, though case complexity has increased.

Occupancy declined to 69% from 73% last year, with medical admissions dropping 6% due to seasonality. Management targets 70% but faces structural challenges from shorter ALOS.

Pre-opening costs of ~₹150 crore EBITDA losses from six new hospitals could pressure consolidated margins, especially in H1 FY27.

Specialty care within AHL faces serious competition in diagnostics, impacting growth. Management acknowledged headwinds but provided limited mitigation details.

Start-up losses of ~₹150 crore from new hospitals could drag consolidated margins if occupancy ramps slower than expected.

Some insurance contracts faced delays in renewal, impacting payor mix; management noted delays but expects resolution.

GST changes and insurance revenue deferral caused a ~₹70 crore mismatch, pushing break-even; sustainability of growth needs monitoring.

New hospitals may take longer to break even than the guided 12 months, with total losses of ~₹150 crore over two years.

The change in GMV reporting (excluding existing customer revenue) could lead to misinterpretation of growth trends.

Despite a significant CGHS rate hike, management noted that government business still offers a 65% discount to private tariffs, limiting margin benefit.

Competitors are poaching senior doctors; management downplayed risk but recent high-profile departures warrant attention.